الإحصائيات الأساسية
| CIK | 1126234 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lumos Pharma, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-35342 Commission File Number LUMOS PHARMA, INC. (Exact name of registrant as specified in its c |
|
| December 13, 2024 |
LUMOS PHARMA, INC. 4200 Marathon Blvd., Suite 200 Austin, Texas 78756 AW LUMOS PHARMA, INC. 4200 Marathon Blvd., Suite 200 Austin, Texas 78756 December 13, 2024 VIA EDGAR Office of Life Sciences – Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Lumos Pharma, Inc. Request for Withdrawal of Filing of POS AM with respect to Form S-3 (Registration No. 333-239137) Ladies and Gentlemen: On behalf of Lum |
|
| December 12, 2024 |
Exhibit (a)(5)(B) Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma AUSTIN, TX and GREENWICH, CT, December 12, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
ELEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LUMOS PHARMA, INC. Exhibit 3.1 ELEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUMOS PHARMA, INC. FIRST: The name of the corporation is Lumos Pharma, Inc. (the “Corporation”). SECOND: The address of its registered office in the state of Delaware is Corporation Service Company, 251 Little Falls Drive, city of Wilmington, county of New Castle, Delaware 19808. The name of its registered agent at such addr |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 S-8 POS 1 d909649ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. 333-259136 Registration No. 333-237590 Registration No. 333-234644 Registration No. 333-203350 Registration No. 333-186020 Registration No. 333-184880 Registration No. 333-178032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDME |
|
| December 12, 2024 |
SECOND AMENDED AND RESTATED BYLAWS LUMOS PHARMA, INC. (A DELAWARE CORPORATION) ARTICLE I Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS LUMOS PHARMA, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES SECTION 1.01. Registered Office. The registered office of the corporation in the state of Delaware shall be in the city of Wilmington, county of New Castle, and the name of its registered agent shall be Corporation Service Company. SECTION 1.02. Other Offices. The corporation may also have |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 12, 2024 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization |
|
| December 12, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 POS AM 1 d873575dposam.htm POS AM As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. 333-266966 Registration No. 333-240149 Registration No. 333-239137 Registration No. 333-226366 Registration No. 333-205234 Registration No. 333-185721 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-3 Registrat |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Lumos Pharma, Inc. (Name of Subject Company) Lumos Pharma, Inc. (Name of Persons Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 55028X 109 (CUSIP Number |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 POS AM 1 d873575dposam.htm POS AM As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. 333-266966 Registration No. 333-240149 Registration No. 333-239137 Registration No. 333-226366 Registration No. 333-205234 Registration No. 333-185721 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-3 Registrat |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
CONTINGENT VALUE RIGHT AGREEMENT Exhibit 2.2 CONTINGENT VALUE RIGHT AGREEMENT This CONTINGENT VALUE RIGHT AGREEMENT, dated as of December 12, 2024 (this “Agreement”), is entered into by and DPV Parent, Inc., a Delaware corporation (“Parent”), and Computershare Inc., a Delaware corporation (“Computershare”) and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company, collectively as Rights Agent (the |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| December 12, 2024 |
As filed with the Securities and Exchange Commission on December 12, 2024 As filed with the Securities and Exchange Commission on December 12, 2024 Registration No. |
|
| November 29, 2024 |
CORRESP November 29, 2024 Via EDGAR Division of Corporation Finance Office of Mergers and Acquisitions U. |
|
| November 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Lumos Pharma, Inc. (Name of Subject Company) Lumos Pharma, Inc. (Name of Persons Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 55028X 109 (CUSIP Number |
|
| November 25, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 19, 2024 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization |
|
| November 25, 2024 |
Exhibit 99.1 Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action AUSTIN, TX, November 21, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new ana |
|
| November 14, 2024 |
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT Exhibit (e)(30) AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT Amendment No. 2 (“Amendment”) to the Employment Agreement between: Dr. Pisit Pitukcheewanont (“Executive”), an individual; and Lumos Pharma, Inc. (“Company”), a Delaware corporation with an office at 4200 Marathon Suite 200 Austin, Texas 78756. WHEREAS 1. The Parties entered into an Employment Agreement, dated May 9, 2022, and amended June 29 |
|
| November 14, 2024 |
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT Exhibit (e)(29) AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT Amendment No. 1 (“Amendment”) to the Employment Agreement between: Dr. Pisit Pitukcheewanont (“Executive”), an individual; and Lumos Pharma, Inc. (“Company”), a Delaware corporation with an office at 4200 Marathon Suite 200 Austin, Texas 78756. WHEREAS 1. The Parties entered into an Employment Agreement, dated May 9, 2022 (“Agreement”); 2. Se |
|
| November 14, 2024 |
Exhibit (e)(24) EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of May 9, 2022 (the “Effective Date”), by and between Lumos Pharma, Inc. |
|
| November 14, 2024 |
Exhibit (e)(25) EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of this 8th day of April, 2020, by and between Lumos Pharma, Inc. |
|
| November 14, 2024 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 13, 2024 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of Lumos Pharma, Inc. |
|
| November 13, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Lumos Pharma, Inc. |
|
| November 13, 2024 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of Lumos Pharma, Inc. |
|
| November 13, 2024 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of Lumos Pharma, Inc. |
|
| November 13, 2024 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| November 13, 2024 |
Exhibit (d)(5) Confidentiality Agreement This Confidentiality Agreement (the “Agreement”) is between Lumos Pharma, Inc. |
|
| November 13, 2024 |
Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of Lumos Pharma, Inc. |
|
| November 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Lumos Pharma, Inc. |
|
| November 12, 2024 |
SC 13G 1 lumo93024.htm PRIVATE ADVISOR GROUP, LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LUMOS PHARMA INC (Name of Issuer) Common Stock (Title of Class of Securities) 55028X109 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| November 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2024. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-353 |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 22, 2024 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| October 23, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among DPV PARENT, INC., DPV MERGERSUB, INC. and LUMOS PHARMA, INC. Dated as of October 22, 2024 TABLE OF CONTENTS Page ARTICLE I THE OFFER Section 1.1 The Offer 2 Section 1.2 Offer Documents 3 Section 1.3 Company Actions 4 ARTICLE II THE MERGER Section 2.1 The Merger 5 Section 2.2 Closing 5 Section 2.3 Effective Time 5 Section 2.4 Effects of the Merger 6 Se |
|
| October 23, 2024 |
Exhibit 99.1 Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) - Lumos Pharma and the FDA Align on Final Design for Global, Double-blinded, Placebo-Controlled Phase 3 Trial Evaluating Oral LUM-201 in PGHD AUSTIN, TX, October 23, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDA |
|
| October 23, 2024 |
Exhibit 99.4 Town Hall Script Thank you for joining on such short notice. I’m sure you saw my email and the press release about our announcement this morning. This announcement marks the beginning of an exciting new journey for Lumos 3.0 and our team. I want to take a few moments to explain the details and also answer your questions. In simple terms, we are being purchased and taken private by Dou |
|
| October 23, 2024 |
CONTINGENT VALUE RIGHT AGREEMENT Exhibit 10.1 CONTINGENT VALUE RIGHT AGREEMENT This Contingent Value Right Agreement, dated as of [●], 2024 (this “Agreement”), is entered into by and DPV Parent, Inc., a Delaware corporation (“Parent”), and [RIGHTS AGENT], a [●], as Rights Agent (the “Rights Agent”). RECITALS WHEREAS, Parent, DPV Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Purchaser”), Lumos Ph |
|
| October 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Lumos Pharma, Inc. (Name of Subject Company) Lumos Pharma, Inc. (Name of Persons Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 55028X 109 (CUSIP Number of Class of Securi |
|
| October 23, 2024 |
Exhibit 10.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of October 22, 2024, is entered into by and among DPV Parent, Inc., a Delaware corporation (“Parent”), DPV MergerSub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), and the Person or Persons set forth on Schedule A hereto (“Stockholder”). All capitalized term |
|
| October 23, 2024 |
Exhibit 99.5 Employee Q&A Q: Will there be any changes in leadership, management, or organization? A: Double Point intends to retain operational continuity with the existing leadership team and Senior Management is expected to continue to lead the organization through the transition and will work with Double Point to finalize the operational plan. Q: Will there be any layoffs? A: As stated, Double |
|
| October 23, 2024 |
Exhibit 99.3 Message for suppliers: Today marks the beginning of an exciting new chapter for Lumos. We are pleased to announce Lumos is being purchased by Double Point Ventures, a firm that invests in companies developing cutting-edge therapeutics. Lumos will transition from a publicly held to a privately held company once the transaction is complete, which is expected before the end of 2024, subj |
|
| October 23, 2024 |
Exhibit 99.1 Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR) - Lumos Pharma and the FDA Align on Final Design for Global, Double-blinded, Placebo-Controlled Phase 3 Trial Evaluating Oral LUM-201 in PGHD AUSTIN, TX, October 23, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDA |
|
| October 23, 2024 |
CLINICAL TRIAL FUNDING AGREEMENT Exhibit 10.3 CLINICAL TRIAL FUNDING AGREEMENT This Clinical Trial Funding Agreement (this “Agreement”) is made as of October 22, 2024 (the “Effective Date”) by and between Double Point Ventures LLC, a Delaware limited liability company (“Lender”) and Lumos Pharma, Inc., a Delaware corporation (“Borrower”). RECITALS WHEREAS, Borrower is a clinical-stage biopharmaceutical company focused on identify |
|
| October 23, 2024 |
Exhibit 99.2 October 23, 2024 Subject: Exciting New Chapter for Lumos – Town Hall team meeting My fellow Lumosians, I know you have all patiently awaited news on our future and our strategy. Today marks the beginning of an exciting new journey for Lumos. We’ve announced that we entered into a definitive agreement to be acquired by Double Point Ventures, a firm that invests in companies developing |
|
| August 2, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2024. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LU |
|
| August 1, 2024 |
Exhibit 99.1 Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, |
|
| August 1, 2024 |
1 Q2 2024 Financial Results, Clinical & Strategic Update August 1, 2024 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 1, 2024 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (C |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 5, 2024 (May 31, 2024) Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or org |
|
| June 5, 2024 |
1 Corporate & Clinical Overview May 2024 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| June 5, 2024 |
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 Exhibit 99.1 Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 AUSTIN, TX, June 4, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annu |
|
| May 15, 2024 |
Exhibit 99.1 Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Mont |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 15, 2024 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (Com |
|
| May 15, 2024 |
1 End-of-Phase 2 FDA Meeting Review Clinical Update Q1 2024 Financial Results May 15, 2024 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| May 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2024. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 L |
|
| April 22, 2024 |
Exhibit 97.1 LUMOS PHARMA, INC. COMPENSATION RECOVERY POLICY As adopted on November 7, 2023 Lumos Pharma, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Compensation Committee (the “Committee”) of the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is in |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2023. OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 L |
|
| April 18, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 18, 2024 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (C |
|
| April 18, 2024 |
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings AUSTIN, TX, April 18, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data fro |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive |
|
| March 20, 2024 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042 AUSTIN, TX, March 20, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, annou |
|
| March 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 20, 2024 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (C |
|
| March 7, 2024 |
Exhibit 21.1 SUBSIDIARIES OF LUMOS PHARMA, INC. Subsidiary Jurisdiction of Incorporation NewLink International Cayman Islands BlueLink Pharmaceuticals, Inc Delaware BioProtection Systems Corporation Delaware Lumos Pharma Sub, Inc. Delaware |
|
| March 7, 2024 |
1 Full Year 2023 Financial Results & Clinical Update March 7, 2024 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| March 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 7, 2024 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (Co |
|
| March 7, 2024 |
Exhibit 99.1 Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Pisit “Duke” Pitukcheewanont, MD, Appoin |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2023. OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUM |
|
| February 6, 2024 |
LUMO / Lumos Pharma, Inc. / WELLS FARGO & COMPANY/MN Passive Investment SC 13G 1 wflumospharma55028X109.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) LUMOS PHARMA INC (Name of Issuer) Common Stock (Title of Class of Securities) 55028X109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 4, 2024 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) ( |
|
| January 4, 2024 |
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer AUSTIN, TX, January 4, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer (CMO), eff |
|
| November 29, 2023 |
LUMO / Lumos Pharma Inc / Blackstone Holdings II L.P. - SC 13D/A Activist Investment SC 13D/A 1 d605126dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lumos Pharma, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 651511107 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 314 Main Street, 15th Floor Cambridge, MA 02142 |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 15, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| November 15, 2023 |
1 Corporate & Clinical Overview November 2023 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| November 7, 2023 |
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 •OraGrowtH210 Results Show LUM-201 Dose of 1. |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 7, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| November 7, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 7, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| November 7, 2023 |
1 Phase 2 Topline Results LUM-201 for Pediatric Growth Hormone Deficiency OraGrowtH210 and OraGrowtH212 November 2023 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| November 7, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2023. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-353 |
|
| November 7, 2023 |
Exhibit 99.1 Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates - Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 – - OraGrowtH210 Trial Results Show LUM-201 Dose of 1.6 mg/kg Achieves AHVs of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Consistent wi |
|
| September 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 September 26, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization |
|
| September 26, 2023 |
Exhibit 99.1 Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting •Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children •Analysis Shows Annualized Height Velocity Increased ~62% Compared to Baseline •Data Support LUM-201 Mechanism of Action in Moderate PGHD Patient Pop |
|
| August 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2023. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LU |
|
| August 9, 2023 |
lumoq22023slidesfinalv1 1 Second Quarter 2023 Financial Results & Clinical Update August 9, 2023 2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. |
|
| August 9, 2023 |
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update Exhibit 99.1 Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update •Confirms Timing for Primary Outcome Data Readout for two Phase 2 OraGrowtH Trials in Q4 2023 •Late Breaking Abstract Accepted for Oral Presentation at ESPE 2023 •Encouraging Interim Data from OraGrowtH Trials Presented at ENDO 2023, Highlighted in KOL Webinar •Conference Call Scheduled for Today at 4 |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 9, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (C |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 28, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (Co |
|
| June 28, 2023 |
Lumos Pharma Announces Departure of Chief Medical Officer Lumos Pharma Announces Departure of Chief Medical Officer AUSTIN, TX, June 28, 2023 – Lumos Pharma, Inc. |
|
| June 21, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 21, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (Co |
|
| June 21, 2023 |
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, TX, June 21, 2023 – Lumos Pharma, Inc. |
|
| June 21, 2023 |
lumokol3presentationdeck 1 KOL Event Response to LUM-201 in Moderate PGHD Fernando Cassorla, MD and Michael Tansey, MD June 21, 2023 2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. |
|
| June 20, 2023 |
LUMO / Lumos Pharma Inc / Farb Daniel Stuart - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Lumos Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55028X109 (CUSIP Number) Scott D. Pomfret, Regulatory Counsel LLC, 43 Commercial St., Provincetown MA (617) 680-5482 (Name, Address and Telephone Number of Person Authorized |
|
| June 2, 2023 |
LUMO / Lumos Pharma Inc / Farb Daniel Stuart - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Lumos Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55028X109 (CUSIP Number) Scott D. Pomfret, Regulatory Counsel LLC, 43 Commercial St., Provincetown MA (617) 680-5482 (Name, Address and Telephone Number of Person Authorized |
|
| May 25, 2023 |
LUMO / Lumos Pharma Inc / Farb Daniel Stuart - FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Lumos Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55028X109 (CUSIP Number) Scott D. Pomfret, Regulatory Counsel LLC, 43 Commercial St., Provincetown MA (617) 680-5482 (Name, Address and Telephone Number of Person Authorized |
|
| May 15, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 15, 2023 (May 10, 2023) Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or org |
|
| May 8, 2023 |
Exhibit 99.1 Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES) Oral and Poster Presentations on OraGrowtH Trials at PES 2023 Further Support Potential for LUM-201 as First Oral Treatment for Moderate Idiopathic PGHD OraGrowtH212 Interim Data Demonstrate LUM-201 Amplifies Natural Pulsatile GH-Secretion and that IGF-1 SDS and Serum Conc |
|
| May 8, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 8, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (Comm |
|
| May 5, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2023. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 L |
|
| May 3, 2023 |
lumoq12023slidesfinal 1 First Quarter 2023 Financial Results & Clinical Update May 3, 2023 2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 3, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (Comm |
|
| May 3, 2023 |
Exhibit 99.1 Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates - Patient Enrollment Completed in both Phase 2 OraGrowtH Trials - - Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 - - Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 – - Conference Call Scheduled for Today at 4:30pm ET - AUSTIN, TX, May 3, 2023 – Lumos Pharma |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 6, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (Co |
|
| March 7, 2023 |
Exhibit 21.1 SUBSIDIARIES OF LUMOS PHARMA, INC. Subsidiary Jurisdiction of Incorporation NewLink International Cayman Islands BlueLink Pharmaceuticals, Inc Delaware BioProtection Systems Corporation Delaware Lumos Pharma Sub, Inc. Delaware |
|
| March 7, 2023 |
EX-99.1 2 lumo-20230306x8kxex991.htm EX-99.1 Exhibit 99.1 Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics of OraGrowtH210 Trial Subjects Highlighted in Poster Presentation AUSTIN, TX, March 5 |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2022. OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUM |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 1, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (Co |
|
| March 1, 2023 |
Exhibit 99.1 Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates - Patient Enrollment Completed in OraGrowtH210 and OraGrowtH212 Trials - - Primary Outcome Data for both OraGrowtH Trials Expected Q4 2023 - - Additional Data from OraGrowtH Trials to be Presented at IMPE 2023 - - Conference Call Scheduled for Today at 4:30 ET - AUSTIN, TX, March 1, 2023 – Lum |
|
| March 1, 2023 |
lumoq42022slidesfinalv1 1 Full Year 2022 Financial Results & Clinical Update March 1, 2023 2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 28, 2023 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| February 28, 2023 |
EX-99.1 2 lumo-20230228x8kxex991.htm EX-99.1 Exhibit 99.1 Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled Primary Outcome Data for Both OraGrowtH Trials Expected 4Q 2023 AUSTIN, TX, February 28, 2023 – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopha |
|
| February 15, 2023 |
LUMO / Lumos Pharma Inc / Farb Daniel Stuart - FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Lumos Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55028X109 (CUSIP Number) Scott D. Pomfret, Regulatory Counsel LLC, 43 Commercial St., Provincetown MA (617) 680-5482 (Name, Address and Telephone Number of Person Authorized to |
|
| January 24, 2023 |
LUMO / Lumos Pharma Inc / Farb Daniel Stuart - FORM SC 13G/A Passive Investment SC 13G/A 1 formsc13ga.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Lumos Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55028X109 (CUSIP Number) January 25, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desig |
|
| December 12, 2022 |
1 KOL Event December 6, 2022 2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. |
|
| December 12, 2022 |
KOL Review of Lumos Pharma?s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients AUSTIN, TX, December 12, 2022 ? Lumos Pharma, Inc. |
|
| December 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 December 12, 2022 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| December 1, 2022 |
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD AUSTIN, Texas, November 29, 2022 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of |
|
| December 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 29, 2022 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2022. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-353 |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 14, 2022 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| November 14, 2022 |
allinclusivelumoscorpora 1 Interim Analysis OraGrowtH210 & OraGrowtH212 November 14, 2022 2 Forward Looking Statements This presentation contains proprietary and confidential information of Lumos Pharma, Inc. |
|
| November 14, 2022 |
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency -LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) - -Interim results for approximately 50% enrollment (n=41) of OraGrowtH210 Trial demonstrated a mean annualized height velocity (AHV) of 8. |
|
| November 14, 2022 |
Exhibit 99.1 Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates - Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six months for the LUM-201 Dose of 1.6 mg/kg/day in the OraGrowtH210 Trial which Supports Advanced Planni |
|
| November 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 14, 2022 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| August 29, 2022 |
Up to $17,800,000 Common Stock 424B5 1 lumo-20220829x424b5.htm 424B5 PROSPECTUS SUPPLEMENT (To Prospectus dated August 26, 2022) Up to $17,800,000 Common Stock Lumos Pharma, Inc. (“we,” “us,” or “our”) has entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, par value $0.01 per share, offered by this prospectu |
|
| August 24, 2022 |
Lumos Pharma, Inc. 4200 Marathon Blvd #200 Austin, Texas 78756 August 24, 2022 Lumos Pharma, Inc. 4200 Marathon Blvd #200 Austin, Texas 78756 August 24, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Lumos Pharma, Inc. Registration Statement on Form S-3 Filed August 19, 2022 File No. 333-266966 Acceleration Request Requested Date:??August 26, 2022 Requested Time:??4:30 p.m. (Eastern time), or as |
|
| August 19, 2022 |
Exhibit 4.3 LUMOS PHARMA, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment of Terms |
|
| August 19, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) LUMOS PHARMA, INC. |
|
| August 19, 2022 |
As filed with the Securities and Exchange Commission on August 18, 2022 As filed with the Securities and Exchange Commission on August 18, 2022 Registration No. |
|
| August 10, 2022 |
EXHIBIT 32.1 CERTIFICATION Pursuant to the requirements set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Richard J. Hawkins, Chief Executive Officer of Lumos Pharma, Inc. (the “Company”), and Lori Lawley, Chief Financial Officer of the Company, each hereby ce |
|
| August 10, 2022 |
Certification of principal financial officer required by Rule 13a-14(a) / 15d-14(a) EXHIBIT 31.2 CERTIFICATION I, Lori Lawley, certify that: 1.I have reviewed this Form 10-Q of Lumos Pharma, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by |
|
| August 10, 2022 |
1 Second Quarter 2022 Financial Results & Clinical Update August 9, 2022 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| August 10, 2022 |
Exhibit 99.1 Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates - Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 - - Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24 Patients Anticipated from OraGrowtH212 Trial - - Cash Runway into Second Quarter 2024 - AUSTIN, TX, Au |
|
| August 10, 2022 |
Certification of principal executive officer required by Rule 13a-14(a) / 15d-14(a) EXHIBIT 31.1 CERTIFICATION I, Richard J. Hawkins, certify that: 1.I have reviewed this Form 10-Q of Lumos Pharma, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period cov |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 9, 2022 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (C |
|
| August 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2022. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LU |
|
| May 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2022. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 L |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 10, 2022 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (Com |
|
| May 10, 2022 |
1 First Quarter 2022 Financial Results & Clinical Update May 10, 2022 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| May 10, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates -Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022- -FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold- -Clinical Collaboration Initiated with Ma |
|
| May 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 9, 2022 (May 4, 2022) Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organ |
|
| May 6, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial ?The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA - AUSTIN, TX, May 5, 2022 (GL |
|
| May 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 6, 2022 (May 5, 2022) Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organ |
|
| April 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 11, 2022 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (C |
|
| April 11, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD ? Interim Data Anticipated by End of 2022 - ?Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - AUSTIN, TX, April 11, 2022 (GLOBE NEWSWIRE) ? Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused o |
|
| March 23, 2022 |
DEF 14A 1 lumo-def14ax2022.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as perm |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 11, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Lumos Pharma, Inc. (the ?Company?, ?Lumos?, ?we?, ?our? or ?us?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following summary of the terms of our common stock, is b |
|
| March 11, 2022 |
Form of Indemnity Agreement by and between the Registrant and its directors and officers Exhibit 10.20 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) dated as of , is made by and between LUMOS PHARMA, INC, a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company?s bylaws (the ?Bylaws?) require that the Compa |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2021. OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUM |
|
| March 11, 2022 |
Exhibit 21.1 SUBSIDIARIES OF LUMOS PHARMA, INC. Subsidiary Jurisdiction of Incorporation NewLink International Cayman Islands BlueLink Pharmaceuticals, Inc Delaware BioProtection Systems Corporation Delaware Lumos Pharma Sub, Inc. Delaware |
|
| March 11, 2022 |
Amended and Restated Certificate of Incorporation filed on November 16, 2011, as amended Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUMOS PHARMA, INC. (AS AMENDED THROUGH MARCH 18, 2020)1 *********** I The name of this company is Lumos Pharma, Inc. (the ?Company?). II. The address of the registered office of the Company in the State of Delaware is: 2711 Centerville Road, Suite 400 Wilmington, DE 19808 County of New Castle The name of the Company?s registered agen |
|
| March 10, 2022 |
Exhibit 99.1 Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral LUM-201 in PGHD anticipated by the end of 2022 AUSTIN, TX, March 10, 2022 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 10, 2022 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) (C |
|
| March 10, 2022 |
1 Full Year 2021 Financial Results & Clinical Update March 10, 2022 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| February 2, 2022 |
LUMO / Lumos Pharma Inc / Farb Daniel Stuart - FORM SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lumos Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55028X109 (CUSIP Number) January 27, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 1, 2022 |
LUMO / Lumos Pharma Inc / Farb Daniel Stuart - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lumos Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55028X109 (CUSIP Number) January 27, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lumos Pharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 55028X109 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Address |
|
| November 5, 2021 |
Employment Agreement, dated August 3, 2021, by and between the Registrant and David Karpf EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made as of August 3, 2021 (the ?Effective Date?), by and between Lumos Pharma, Inc. |
|
| November 5, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2021. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-353 |
|
| November 3, 2021 |
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates ?Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sites ?Six-month primary outcome data readout from OraGrowtH210 expected 2H 2023 AUSTIN, TX, November 3, 2021 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinic |
|
| November 3, 2021 |
1 Third Quarter 2021 November 3, 2021 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 3, 2021 Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation or organization) |
|
| August 30, 2021 |
LUMO / Lumos Pharma Inc / SHV Management Services II, LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Lumos Pharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 55028X109 (CUSIP Number) Jason Brandt c/o Sant? Ventures 201 West 5th Street, Suite 1500 Austin, Texas 78701 (512) 721-1200 (Name, Address and Telephone Numbe |
|
| August 27, 2021 |
As filed with the Securities and Exchange Commission on August 27, 2021 Registration No. |
|
| August 23, 2021 |
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X RICKEY ELY, Derivatively on Behalf of Nominal Defendant NEWLINK GENETICS CORPORATION, Plaintiff, vs. |
|
| August 23, 2021 |
UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X RICKEY ELY, Derivatively on Behalf of Nominal Defendant NEWLINK GENETICS CORPORATION, Plaintiff, vs. |
|
| August 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 23, 2021 (August 10, 2021) Date of Report (date of earliest event reported) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction of incorporation |
|
| August 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2021. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LU |
|
| August 6, 2021 |
Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT Amendment No. 1 (?Amendment?) to the Employment Agreement between: LORI LAWLEY, an individual; and LUMOS PHARMA, INC., (formerly, ?NewLink Genetics Corporation?) a Delaware corporation with an office at 4200 Marathon Suite 200 Austin, Texas 78756. WHEREAS 1.The Parties entered into an Employment Agreement, dated September 30, 2019 (?Agreement?); |
|
| August 6, 2021 |
Exhibit 10.2 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT Amendment No. 1 (?Amendment?) to the Employment Agreement between: DR. JOHN MCKEW, an individual; and LUMOS PHARMA, INC., (formerly, ?NewLink Genetics Corporation?) a Delaware corporation with an office at 4200 Marathon Suite 200 Austin, Texas 78756. WHEREAS 1.The Parties entered into an Employment Agreement, dated March 27, 2020 (?Agreement?); |
|
| August 5, 2021 |
EX-99.2 3 a2021q2slides.htm PRESENTATION 1 Second Quarter 2021 August 5, 2021 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. (the “Company”) that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of |
|
| August 5, 2021 |
EX-99.1 2 lumo-2021q2x8kxex991.htm PRESS RELEASE Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates • Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board • Screening and enrol |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| August 3, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer AUSTIN, TX, August 3, 2021 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, David B. Karpf, MD, joined the Company |
|
| August 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 (July 30, 2021) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Em |
|
| August 2, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President AUSTIN, TX, August 2, 2021 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew, PhD, was promoted t |
|
| July 21, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2021 (July 20, 2021) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Emp |
|
| July 21, 2021 |
Lumos Pharma Announces Clinical Updates Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Announces Clinical Updates ?OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 months ?OraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be extended to 12 months with primary data at 6-months ?Cash balance as of June 30, 2021 of $107.7 million (unaudited) expected |
|
| June 28, 2021 |
Exhibit 99.1 For Immediate Release Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels AUSTIN, TX, June 28, 2021 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutic |
|
| June 28, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| May 26, 2021 |
LUMO / Lumos Pharma Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| May 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2021 (May 19, 2021) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Emplo |
|
| May 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 31, 2021. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 L |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| May 5, 2021 |
1 First Quarter 2021 May 5, 2021 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| May 5, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates ? Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely to respond to LUM-201 ? Data presented at ENDO 2021 differentiate LUM-201 from standard GH secretagogue |
|
| April 29, 2021 |
1 Pediatric Growth Hormone Deficiency and LUM-201 KOL Event April 27, 2021 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| April 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 (April 27, 2021) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS E |
|
| April 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| April 27, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar Virtual KOL Event is scheduled for Today, April 27th @ 10:30 AM ET AUSTIN, TX, April 27, 2021 (GLOBE NEWSWIRE) ? Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for r |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 (April 16, 2021) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS E |
|
| April 21, 2021 |
Exhibit 99.1 Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession ?Eddie L. Varnado joins Lumos Pharma as Vice President, Finance and Corporate Controller AUSTIN, TX, April 20, 2021 - Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to i |
|
| April 14, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2021 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| April 14, 2021 |
Exhibit 99.1 Lumos Pharma to Host Key Opinion Leader Event on LUM-201 for the Treatment of Pediatric Growth Hormone Deficiency Virtual KOL Event is scheduled for Tuesday, April 27th @ 10:30 AM ET AUSTIN, Texas, April 14, 2021 - Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that it will host a key opinion lea |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 23, 2021 |
Exhibit 99.1 Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency Data show greater GH response in pediatric growth hormone deficiency (PGHD) from LUM-201 than standard GH secretagogues AUSTIN, TX, March 20, 2021 - Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-st |
|
| March 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 (March 20, 2021) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS E |
|
| March 9, 2021 |
Form of Indemnity Agreement by and between the Registrant and its directors and officers Exhibit 10.20 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) dated as of , is made by and between LUMOS PHARMA, INC, a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company?s bylaws (the ?Bylaws?) require that the Compa |
|
| March 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| March 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2020. OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LUM |
|
| March 9, 2021 |
Full Year 2020 Financial Results and Corporate Update March 9, 2021 This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| March 9, 2021 |
Amended and Restated Certificate of Incorporation filed on November 16, 2011, as amended EX-3.1 2 lumo-20201231x10xkxex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LUMOS PHARMA, INC. (AS AMENDED THROUGH MARCH 18, 2020)1 *********** I The name of this company is Lumos Pharma, Inc. (the “Company”). II. The address of the registered office of the Company in the State of Delaware is: 2711 Centerville Road, Suite 400 Wilmington, DE 19808 County of New Cast |
|
| March 9, 2021 |
Exhibit 21.1 SUBSIDIARIES OF LUMOS PHARMA, INC. Subsidiary Jurisdiction of Incorporation NewLink International Cayman Islands BlueLink Pharmaceuticals, Inc Delaware BioProtection Systems Corporation Delaware Lumos Pharma Sub, Inc. Delaware |
|
| March 9, 2021 |
EX-4.2 3 lumo-20201231x10xkxex42.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Lumos Pharma, Inc. (the “Company”, “Lumos”, “we”, “our” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. The following su |
|
| March 9, 2021 |
Exhibit 99.1 Lumos Pharma Reports Full Year 2020 Financial Results and Provides Update on OraGrowtH Trials in PGHD ?Data published in the Journal of Endocrine Society and accepted for presentation at ENDO 2021 demonstrate distinct mechanism of action and potential efficacy of LUM-201 in subset of pediatric growth hormone deficiency (PGHD) patients ?Final tranche of $26 million non-dilutive funds f |
|
| March 4, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| March 4, 2021 |
Exhibit 99.1 Data Supporting Use of Predictive Enrichment Markers for Lumos Pharma?s LUM-201 Therapy in Clinical Trials for Moderate PGHD Published in Journal of the Endocrine Society Data Analysis Supports Use of Predictive Enrichment Markers in Phase 2b OraGrowtH210 Trial AUSTIN, TX, March 4, 2021 - Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeu |
|
| March 2, 2021 |
Exhibit 99.1 Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting AUSTIN, TX, March 2, 2021 ? Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, will present poster 7102 at the virtual Endocrine Society 2021 Annual |
|
| March 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| February 16, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Announces Changes to its Board of Directors ?Lumos Pharma appoints new Board member, An van Es-Johansson, M.D., with wealth of experience in rare diseases AUSTIN, TX, February 16, 2021 - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment of An van Es-Johans |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2021 (February 10, 2021) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Lumos Pharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 55028X109 (CUSIP Number) December 31, 202 |
|
| February 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 (February 4, 2021) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (I |
|
| December 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2020 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| December 30, 2020 |
Sales Agreement, dated December 30, 2020, between the Registrant and Cantor Fitzgerald & Co. EX-10.1 3 lumo-20201230x8kxex101.htm EX-10.1 Exhibit 10.1 LUMOS PHARMA, INC Shares of Common Stock (par value $0.01 per share) Controlled Equity OfferingSM Sales Agreement December 30, 2020 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Lumos Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co |
|
| December 30, 2020 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-226366 PROSPECTUS SUPPLEMENT (To Prospectus dated July 22, 2019) Up to $50,000,000 Common Stock Lumos Pharma, Inc., formerly known as NewLink Genetics Corporation (“we,” “us,” or “our”), has entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2020 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| December 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| November 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended September 30, 2020. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-353 |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of inc |
|
| November 10, 2020 |
Third Quarter 2020 Financial Results and Corporate Update November 10, 2020 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| November 10, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results ? Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients with data read-out anticipated mid-year 2022 AUSTIN, TX, November 10, 2020 - Lumos Pharma, Inc. (NASDAQ:LUMO), |
|
| August 14, 2020 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN LUMOS PHARMA, INC. AND MERCK SHARP & DOHME CORP. July 27, 2020 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 27, 2020 (the “Effective Date”), by and between Merck Sharp & Dohme Corp. (“Merck”) and Lumos Pharma, Inc. (“Lumos”). Merck and Lumos may hereinafter be referred to individua |
|
| August 14, 2020 |
Amendment No. 1 as of August 12, 2020 to Lumos Merck Agreement with Merck Exhibit 10.2 AMENDMENT NO. 1 TO LICENSE AGREEMENT This AMENDMENT NO. 1 TO LICENSE AGREEMENT made as of August 12, 2020 (the “Amendment Date”) is made by and between MERCK SHARP & DOHME CORP., a New Jersey corporation (“Merck”) and Lumos Pharma, Inc. (“Lumos”), a Delaware corporation (this “Amendment”), pursuant to that certain License Agreement dated October 22, 2013, by and between Merck and Ammo |
|
| August 14, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2020. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 LU |
|
| August 13, 2020 |
q22020slides81220finalv1 Second Quarter 2020 Financial Results and Corporate Update August 13, 2020 Lumos Pharma Q2 2020 Conference Call • Lisa Miller, Director of Investor Relations • Rick Hawkins, CEO Agenda • John McKew, PhD, COO & CSO • Eugene Kennedy, MD, CMO • Carl Langren, CFO 2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. |
|
| August 13, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities • Lumos Pharma sells Priority Review Voucher (PRV), valued at $100 million - Lumos Pharma to receive $60 million for its 60% interest in PRV • Lumos Pharma reaffirms its expectation of the initiation of its Phase 2b LUM-201 trial in Pediatric Growth Hormone D |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| August 10, 2020 |
4,146,398 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-240149 PROSPECTUS 4,146,398 Shares of Common Stock This prospectus relates to the resale from time to time of up to 4,146,398 shares of common stock of Lumos Pharma, Inc. (the “Company,” “we,” “us” or “ours”), formerly known as NewLink Genetics Corporation (“NewLink”), by the selling stockholders listed on page 3. Such shares were issued or are |
|
| August 5, 2020 |
August 5, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Attention: Abby Adams Re: Lumos Pharma, Inc. Registration Statement on Form S-3 Filed July 28, 2020 File No. 333-240149 Acceleration Request Requested Date: August 7, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: P |
|
| August 3, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 (July 28, 2020) LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Em |
|
| July 28, 2020 |
Power of attorney (included on the signature page to the registration statement) As filed with the Securities and Exchange Commission on July 28, 2020 Registration No. |
|
| July 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 LUMOS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-35342 42-1491350 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| July 27, 2020 |
Lumos Pharma Announces Sale of Priority Review Voucher Exhibit 99.1 Lumos Pharma Announces Sale of Priority Review Voucher AUSTIN, TX, July 27, 2020 (GLOBE NEWSWIRE) - Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (PRV) to Merck, known as MSD outside the United States and Canada. |
|
| July 10, 2020 |
Securities and Exchange Commission July 10, 2020 Lumos Pharma, Inc. 4200 Marathon Blvd. #200 Austin, Texas 78756 July 10, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720 Re: Lumos Pharma, Inc. Registration Statement on Form S-3 Filed June 12, 2020 File No. 333-239137 Ladies and Gentlemen: Pu |
